ELISA: 1: 5000approx. 1: 10000. WB: 1: 500approx. 1: 1000. Other applications not tested. Optimal dilutions are dependent on conditions and should be determined by the user.
CBP20 antikoerper, CG12357 antikoerper, Dmel\\CG12357 antikoerper, 20kDa antikoerper, 5930413E18Rik antikoerper, AA536802 antikoerper, AI843301 antikoerper, C79367 antikoerper, CHUNP6917 antikoerper, zgc:92592 antikoerper, CBC2 antikoerper, NIP1 antikoerper, ATCBP20 antikoerper, CAP-binding protein 20 antikoerper, MLN1.12 antikoerper, MLN1_12 antikoerper, Ncbp2 antikoerper, cap binding protein 20 antikoerper, nuclear cap binding protein subunit 2 antikoerper, nuclear cap binding protein subunit 2, 20kDa antikoerper, nuclear cap binding protein subunit 2 L homeolog antikoerper, nuclear cap-binding protein subunit 2 antikoerper, CAP-binding protein 20 antikoerper, Nuclear cap-binding protein subunit 2 antikoerper, Cbp20 antikoerper, Ncbp2 antikoerper, ncbp2 antikoerper, NCBP2 antikoerper, ncbp2.L antikoerper, CBP20 antikoerper, ncbp-2 antikoerper
Hintergrund
In eukaryotes, the majority of mRNAs have an m(7)G cap, which is added cotranscriptionally and plays a critical role in many aspects of mRNA metabolism. The effect of the cap on translation is mediated by the initiation factor eIF-4F, whereas the effect on pre-mRNA splicing involves a nuclear complex (CBC). CBC consists of two cap binding proteins, CBP20 and CBP80, which mediate the stimulatory functions of the cap in pre-mRNA splicing, 3' end formation and U snRNA export. The genes CBC1 and CBC2 encode CBP80 and CBP20, respectively. CBP80 comprises three domains, each containing a MIF4G domain. CBP20 has an RNAP fold and associates with the second and third domains of CBP80. CBP also plays a role in nonsense-mediated decay (NMD), a process which eliminates mRNAs, and prematurely terminates translation. CBP80-bound mRNA undergoes a pioneer round of translation before CBP80-CBP20 are replaced by eIF4E, and Upf2 and Upf3 proteins.Synonyms: CBP20, Nuclear cap-binding protein subunit 2, PIG55